Authors: Yijun Jia Lei Xu Qing Lin Mingjie Zhu Longlong Ding Kejin Wu Yunshu Lu
Publish Date: 2014/05/06
Volume: 31, Issue: 6, Pages: 981-
Abstract
The aim of this study was to assess associations between ER Ki67 Her2 phenotypes molecular subtypes of breast cancer and circulating levels of lymphocyte subsets CD4+ CD8+ NK CD19+ CD20+ and the ratio of CD4+ to CD8+ prior to treatment Cells from peripheral blood were counted by flow cytometry ER Her2 and Ki67 expressions were detected by pathological examination and Her2 was also detected by FISH We conducted a case–case comparison of 494 women with newly diagnosed breast cancer to evaluate association between levels of lymphocyte subsets in peripheral blood and breast cancer phenotypes ER− vs ER+ Ki67 ≥ 14 vs Ki67 14 Her2+ vs Her2− triplenegative breast cancer TNBC vs luminal A Women with the highest levels of CD3+ OR 045 95 CI 022–094 CD4+ OR 022 95 CI 008–059 and the ratio of CD4+/CD8+ OR 017 95 CI 006–047 were least likely to have TNBCs compared with luminal A cancers The highest tertile of CD8+ OR 367 95 CI 106–1272 and NK OR 264 95 CI 112–624 was significantly associated with TNBC compared with luminal A cancer ER− Ki67 ≥ 14 Her2+ were associated with low levels of CD4+ and CD4+/CD8+ compared with ER+ Ki67 14 Her2− Women in the highest level of CD8+ had more likelihood to have ER− and Her2+ compared with ER+ and Her2− High levels of NK cells were associated with increased risk of ER− compared with ER+ cancers Highest levels of CD19+ and CD20+ were associated with low risk of ER− compared with ER+ cancers These findings show that immune function differs among different breast cancer phenotypes or subtypes and is associated with ER− Her2+ Ki67 ≥ 14 and TNBC which are likely to be aggressive phenotypes
Keywords: